Market Cap: $67.96B
Market Cap: $67.96B
Open
$17.04
Prev. Close
$21.64
High
$17.07
Low
$16.73
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally.
Takeda Pharmaceutical Company Limited trades on the New York Stock Exchange under the ticker TAK, priced in USD.
Takeda Pharmaceutical Company Limited has a market capitalisation of $67.96B, based on its latest share price.
TAK trades at 55.45 times its trailing 12-month earnings.
Over the past 52 weeks TAK has traded between $14.01 and $21.86.
Yes. Takeda Pharmaceutical Company Limited's dividend yields 3.19% at the current share price, paying out 175% of its earnings.
Profitable, with a net margin of 3.9% over the last 12 months.
The analyst consensus rating for TAK is Buy.
Julie So-Young Kim is the CEO of Takeda Pharmaceutical Company Limited, which is headquartered in Tokyo.
Generated automatically from reported financial data. General information only, not financial advice.
Takeda Pharmaceutical Company (Ticker: TAK) continues to demonstrate robust financial health in the competitive pharmaceutical market, despite facing challenges from generic competition that affects i…
Eli Lilly's Strategic Expansion in Neuroscience: Implications for the Competitive Landscape Eli Lilly and Company takes a significant step in the neuroscience space with its recent announcement to acq…
Takeda Pharmaceutical Company Targets Innovations in Mental Health Treatments In a landscape where mental health disorders impact over 970 million individuals globally, Takeda Pharmaceutical Company r…
Innovative Serotonergic Therapies on the Rise in Mental Health Treatment Helus Pharma is making significant strides in the booming mental health therapeutics market, which is set to surpass $40 billio…